SCHEMBL30446589

SCHEMBL30446589

Cc1ccc(-c2nc3ccccc3s2)cc1NC(=O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.68
▸ RXFP1 Q9HBX9 3/20 0.68
▸ TP53 P04637 7/20 0.65
▸ SMN1; SMN2 Q16637 4/20 0.65
▸ ALDH1A1 P00352 2/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ CYP3A4 P08684 2/20 0.62
▸ CYP2C9 P11712 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ NPSR1 Q6W5P4 2/20 0.61
▸ KDM4E B2RXH2 1/20 0.61
▸ HPGD P15428 1/20 0.61
▸ MAPK14 Q16539 2/20 0.56
▸ SMO Q99835 2/20 0.56
▸ SCD O00767 1/20 0.55
▸ LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25208976 1.00 MAPT (0.68) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL12963468 0.83 MAPT (0.76) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL12935589 0.80 MEN1 (0.76) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL25211272 0.80 TP53 (0.65) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL25211422 0.80 MAPK14 (0.79) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL30445799 0.80 MAPK14 (0.79) MAPTTP53SMN1; SMN2ALDH1A1MEN1
SCHEMBL30445476 0.80 TP53 (0.65) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL24710841 0.79 MAPT (0.72) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL12963241 0.79 MAPT (0.67) MAPTRXFP1TP53SMN1; SMN2ALDH1A1
SCHEMBL25234064 0.79 TP53 (0.66) MAPTRXFP1TP53SMN1; SMN2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230172913-A1 COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172913-A1 COMPOUNDS FOR USE IN THE REACTIVATION OF HIV IN LATENT HIV-INFECTED CELLS TARBP1, NFATC1, TARDBP MAPT 781/4885RXFP1 4545/4885TP53 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback